Greenwich Biosciences Sponsors Several Activities at the 2017 American Epilepsy Society Meeting

Dec 21, 2017

At the AES Annual Meeting 2017 in Washington, DC, Greenwich Biosciences continued its commitment to advance cannabinoid science by sponsoring several events and posters, including:

  • Innovation Pavilion with presentations of Continuum of Care and Cannabinoid Science
  • Scientific Exhibit—Advancing Cannabidiol: GWPCARE Phase III Trials and Results
  • Poster Sessions presenting cannabidiol data from:
    • Open-label Expanded Access Program (EAP) Results
    • Phase 3 Clinical Trial Results
    • Phase 1 Clinical Trial Results
    • Preclinical Study Results

If you’re a U.S. HCP interested in learning more about our clinical trials please contact

These are industry-sponsored programs by Greenwich Biosciences, Inc., a GW Pharmaceuticals plc company. Cannabidiol (CBD) is an investigational drug and not FDA-approved for any indication. These are not CME programs nor will CME/CE credits be given for attendance.

Recent News